deferoxamine has been researched along with losartan potassium in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.71) | 18.7374 |
| 1990's | 41 (58.57) | 18.2507 |
| 2000's | 16 (22.86) | 29.6817 |
| 2010's | 8 (11.43) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, M; Rodday, P; Vitale, JJ | 1 |
| Barosi, G; Bianco, L; Bovio, G; Galli, F; Piazza, V; Picardi, L; Poggio, F; Salvadeo, A; Segagni, S; Villa, G | 1 |
| Coppens, PJ; de Leeuw, PW; Feelders, RA; Vreugdenhil, G | 1 |
| Kawahara, H; Toriyama, T | 1 |
| Kurihara, S; Marumo, F | 1 |
| Cecchin, E; De Marchi, S | 1 |
| Cannata, JB; Diaz López, JB | 1 |
| Harris, DC; Roger, SD; Stewart, JH | 1 |
| de la Serna, FJ; Estenoz, J; Gilsanz, F; Praga, M | 1 |
| Fyhrquist, F; Rosenlöf, K; Tenhunen, R | 1 |
| Brancaccio, D; Gallieni, M; Galmozzi, C; Padovese, P | 1 |
| Lowrey, S | 1 |
| Campise, M; Casati, S; Ponticelli, C | 1 |
| Campise, M; Casati, S; Castelnovo, C; Ponticelli, C | 1 |
| Cairo, MS | 1 |
| Donnelly, SM; Smith, EK | 1 |
| Katz, MA; Kirlin, LF; Ogden, DA; Ruiz, J; Stivelman, JC; Van Wyck, DB | 1 |
| Jenson, BM; Johnson, WJ; McCarthy, JT; Moyer, TP; Nixon, DE | 1 |
| Barbieri, R; Bernardi, F; Buzzoni, D; Conconi, F; Del Senno, L; Gambari, R; Marchetti, G; Perrotta, CM; Piva, MR | 1 |
| Ebert, BL; Firth, JD; Gleadle, JM; Ratcliffe, PJ | 1 |
| Birgegård, G; Danielson, BG; Goch, J; Wikström, B | 1 |
| Cohen, AM; Floru, S; Lewinski, UH; Mittelmann, M | 1 |
| Caparros, G; de la Torre, M; Enríquez de Salamanca, R; Ferreras, I; Fontanellas, A; Nieto, J; Peces, R; Sánchez, A | 1 |
| Semenza, GL; Wang, GL | 1 |
| Alonso, MC; Alonso, R; Arcocha, V; Arza, D; Lens, XM; Novoa, D; Otero, S; Romero, R; Sanchez-Guisande, D | 1 |
| Ahmad, R; Fahal, IH; Helliwell, T; McClelland, P; Roberts, NB; Sallomi, DF; Shivakumar, KA; Yaqoob, M | 1 |
| Ebert, BL; Gleadle, JM; Ratcliffe, PJ | 1 |
| Bartlett, SM; Ebert, BL; Gleadle, JM; O'Rourke, JF; Poulton, J; Ratcliffe, PJ | 1 |
| Eckardt, KU; Gess, B; Göpfert, T; Kurtz, A | 1 |
| Bendix-Hansen, K; Boesen, AM; Christensen, T; Ellegaard, J; Heickendorff, L; Jensen, FT; Jensen, PD; Pedersen, B | 1 |
| Cannata Andía, JB | 1 |
| Baricchi, R; Boiardi, L; Brunati, C; Lasagni, D; Macchioni, P; Piccinini, R; Portioli, I; Salvarani, C | 1 |
| Brooks, DJ; Dos Santos, B; Dragsten, PR; Hedlund, BE; Kling, PJ; Roberts, RA; Taetle, R | 1 |
| Acker, H; Ehleben, W; Fandrey, J; Kummer, W; Porwol, T | 1 |
| Acker, H; Ehleben, W; Fandrey, J; Frede, S; Jelkmann, W; Porwol, T | 1 |
| Juzwiuk, J; Kalinowski, M; Kaliszewski, Z; Popławski, A | 1 |
| Huang, TP; Tarng, DC | 1 |
| Agani, F; Semenza, GL | 1 |
| Fandrey, J; Neumcke, I; Pagel, H; Schneider, B | 1 |
| Bunn, HF; Goldberg, MA; Gu, J; Huang, LE; Willmore, WG | 1 |
| Aucella, F; Carotenuto, M; Musto, P; Prencipe, M; Scalzulli, P; Stallone, C; Valente, GL; Vigilante, M | 1 |
| Daghman, NA; Lappin, TR; Maxwell, AP; McHale, CM; Price, S; Savage, GM; Winter, PC | 1 |
| Daghman, NA; Elder, GE; Lappin, TR; Maxwell, AP; Savage, GA; Winter, PC | 1 |
| Baraban, JM; Hall, D; Lin, KI; Marquis, JC; Miller, MP; O'Donovan, K; Ratan, RR; Ryu, H; Semenza, GL; Zaman, K | 1 |
| Chen, JB; Hsu, KT; Lam, KK; Lee, CT; Liao, SC | 1 |
| Franklin Bunn, H; Horiguchi, H | 1 |
| Dorrington, KL; Maxwell, PH; Ren, X; Robbins, PA | 1 |
| Brunello, F; Camaschella, C; De Gobbi, M; Mazza, U; Paccotti, P; Pasquero, P | 1 |
| Acuña, G; Cannata-Andía, JB; Fernández-Martín, JL; Fernández-Soto, I | 1 |
| Dirnagl, U; Isaev, N; Karsch, M; Megow, D; Meisel, A; Prass, K; Priller, J; Ruscher, K; Scharff, A | 1 |
| Erduran, E; Hacisalihoglu, S; Ozoran, Y | 1 |
| Ueki, M | 1 |
| Hamada, S; Kakinuma, Y; Miura, M; Ohsawa, S; Yagi, T | 1 |
| Köstler, E; Wollina, U | 1 |
| Chang, YS; Ferriero, DM; Mu, D; Vexler, ZS | 1 |
| Andreani, M; Gaziev, J; Lucarelli, G; Polchi, P; Sodani, P | 1 |
| Ehehalt, R; Fein, E; Herrmann, T; Kulaksiz, H; Merle, U | 1 |
| Ding, SJ; Guo, W; Li, YX; Xiao, L; Zhan, Q | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Balanos, GM; Croft, QP; Dorrington, KL; Ratcliffe, PJ; Robbins, PA; Smith, TG; Talbot, NP | 1 |
| Groenendaal, F; Heijnen, CJ; Kavelaars, A; van Bel, F; van der Kooij, MA | 1 |
| Bi, CW; Chan, GK; Choi, RC; Dong, TT; Fu, Q; Guo, AJ; Lau, DT; Tsim, KW; Xu, SL; Zhan, JY; Zheng, KY; Zhu, KY | 1 |
| Rempe, DA; Zhao, Y | 1 |
| Altés, A; De Paz, R; del Cañizo, C; López Arrieta, JM | 1 |
| Boesch-Saadatmandi, C; Ciesla, M; Dulak, J; Jozkowicz, A; Kozakowska, M; Loboda, A; Rimbach, G; Stachurska, A; Wolffram, S | 1 |
| Dirnagl, U; Isaev, NK; Meisel, A; Mergenthaler, P; Muselmann, C; Ruscher, K; Sünwoldt, J; Wieloch, T | 1 |
| Elliott, JP; Jones, SM; Novak, AE | 1 |
| Befani, C; Georgoulias, P; Gkotinakou, IM; Hu, CJ; Liakos, P; Mylonis, I; Simos, G | 1 |
| Fichorova, R; LaRose, S; Lipsitz, LA; Monk, AD; Ryan, S; Sorond, FA; Tan, CO | 1 |
| Chen, CL; Chen, MY; Chen, NC; Ou, SH; Yin, CH | 1 |
5 review(s) available for deferoxamine and losartan potassium
| Article | Year |
|---|---|
Insights into the complex aluminium and iron relationship.
Topics: Aluminum; Animals; Biological Transport, Active; Deferoxamine; Erythropoietin; Humans; Iron; Renal Dialysis | 1991 |
Clinical spectrum of iron overload, novel uses of iron chelators, and potential treatment of pediatric anemias with erythropoietin. Introduction.
Topics: Anemia; Chelation Therapy; Child; Deferoxamine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron; Recombinant Proteins; Transfusion Reaction | 1990 |
Aluminium toxicity: its relationship with bone and iron metabolism.
Topics: Aluminum; Bone and Bones; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failure, Chronic; Parathyroid Hormone | 1996 |
[Recent progress of doping tests in sports].
Topics: Deferoxamine; Doping in Sports; Erythropoietin; Growth Hormone; Humans; Hydroxyethyl Starch Derivatives; Substance Abuse Detection; Substance-Related Disorders | 2003 |
Therapy of porphyria cutanea tarda.
Topics: Chloroquine; Deferoxamine; Erythropoietin; Humans; Iron; Phlebotomy; Porphyria Cutanea Tarda; Renal Dialysis; Sunscreening Agents | 2005 |
7 trial(s) available for deferoxamine and losartan potassium
| Article | Year |
|---|---|
Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
Topics: Adult; Aged; Chelation Therapy; Deferoxamine; Erythropoietin; Female; Ferritins; Hemosiderosis; Humans; Iron; Liver; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Tomography, X-Ray Computed; Transferrin; Uremia | 1991 |
Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common.
Topics: Adult; Aluminum; Chelation Therapy; Deferoxamine; Drug Therapy, Combination; Erythropoietin; Female; Hematopoiesis; Humans; Male; Middle Aged; Recombinant Proteins | 1991 |
Treatment of erythropoietin-resistant anaemia with desferrioxamine in patients on haemofiltration.
Topics: Adult; Aged; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Female; Ferritins; Hemofiltration; Hemoglobins; Humans; Iron; Male; Middle Aged; Recombinant Proteins | 1995 |
Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy.
Topics: Adult; Antibodies, Monoclonal; Blood Cell Count; Carcinoma, Hepatocellular; Cell Hypoxia; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind Method; Erythropoietin; Ferritins; Humans; Iron; Iron Deficiencies; Liver Neoplasms; Male; Neoplasms; Receptors, Transferrin; Tumor Cells, Cultured | 1996 |
Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans.
Topics: Acute Disease; Adolescent; Adult; Carbon Dioxide; Carotid Body; Deferoxamine; Erythropoietin; Female; Humans; Hypoxia; Infusions, Intravenous; Male; Middle Aged; Respiratory Mechanics | 2000 |
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status.
Topics: Adult; Blood Pressure; Cross-Over Studies; Deferoxamine; Erythropoietin; Female; Ferritins; Humans; Hypoxia; Infusions, Intravenous; Iron; Male; Oxygen; Partial Pressure; Pulmonary Artery; Pulmonary Circulation; Siderophores; Young Adult | 2008 |
Deferoxamine, Cerebrovascular Hemodynamics, and Vascular Aging: Potential Role for Hypoxia-Inducible Transcription Factor-1-Regulated Pathways.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Cerebrovascular Circulation; Chelation Therapy; Cross-Over Studies; Deferoxamine; Erythropoietin; Female; Hemodynamics; Humans; Hypoxia-Inducible Factor 1; Male; Middle Aged; Siderophores; Signal Transduction; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Vascular Endothelial Growth Factors; Young Adult | 2015 |
58 other study(ies) available for deferoxamine and losartan potassium
| Article | Year |
|---|---|
Delayed erythropoiesis in irradiated rats grafted with syngeneic marrow: effects of cytotoxic drugs and iron-deficiency anemia.
Topics: Anemia, Hypochromic; Animals; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Deferoxamine; Erythropoiesis; Erythropoietin; Graft Rejection; Immunosuppression Therapy; Male; Radiation Chimera; Rats; Rats, Inbred Lew; Spleen; Time Factors; Transplantation, Isogeneic | 1976 |
Erythropoietin as treatment of haemodialysis-related porphyria cutanea tarda.
Topics: Aged; Deferoxamine; Erythrocytes; Erythropoietin; Humans; Iron; Male; Porphyrias; Porphyrins; Protoporphyrins; Renal Dialysis; Skin Diseases | 1992 |
Possible mechanisms underlying potentiating effects of iron chelators in hematopoietic response to erythropoietin.
Topics: Anemia; Deferoxamine; Drug Synergism; Erythropoietin; Hematopoiesis; Humans; Kidney Failure, Chronic | 1992 |
[Small volume plasma exchange therapy in patients with porphyria cutanea tarda on maintenance hemodialysis].
Topics: Deferoxamine; Erythropoietin; Humans; Kidney Diseases; Male; Middle Aged; Plasma Exchange; Porphyrias; Porphyrins; Recombinant Proteins; Renal Dialysis; Skin Diseases | 1992 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Anemia; Bone Diseases, Metabolic; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failure, Chronic; Metabolic Diseases; Recombinant Proteins; Renal Dialysis | 1992 |
Erythropoietin and improvement in the erythropoiesis of chronic hemodialysis patients treated with desferrioxamine.
Topics: Deferoxamine; Erythropoiesis; Erythropoietin; Hemoglobins; Humans; Kidney Failure, Chronic; Renal Dialysis | 1991 |
Erythropoietin, aluminium, and anaemia in patients on haemodialysis.
Topics: Adult; Aluminum; Anemia, Hypochromic; Deferoxamine; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; Erythrocyte Count; Erythrocytes; Erythropoiesis; Erythropoietin; Female; Ferrochelatase; Humans; Hydroxymethylbilane Synthase; Lyases; Male; Middle Aged; Protoporphyrins; Recombinant Proteins; Renal Dialysis | 1990 |
Desferrioxamine versus erythropoietin for treatment of dialysis anaemia.
Topics: Aluminum; Anemia; Deferoxamine; Erythropoietin; Humans; Renal Dialysis; Time Factors | 1990 |
Case management of the anemic patient epoetin alfa: focus on aluminum management.
Topics: Adult; Aged; Aluminum; Anemia; Deferoxamine; Erythropoietin; Female; Humans; Kidney Failure, Chronic; Male; Poisoning | 1991 |
Aluminium interference in the treatment with recombinant human erythropoietin.
Topics: Aluminum; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Humans; Recombinant Proteins; Uremia | 1990 |
Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
Topics: Adult; Aluminum; Anemia; Deferoxamine; Erythropoietin; Humans; Middle Aged; Recombinant Proteins; Renal Dialysis | 1990 |
The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment.
Topics: Aluminum; Anemia; Biological Availability; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Humans; Iron; Iron Deficiencies; Kidney Failure, Chronic; Middle Aged; Recombinant Proteins; Renal Dialysis | 1990 |
Iron status in patients receiving erythropoietin for dialysis-associated anemia.
Topics: Anemia; Deferoxamine; Erythropoietin; Humans; Iron; Kidney Failure, Chronic; Recombinant Proteins; Renal Dialysis | 1989 |
Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy.
Topics: Adult; Aged; Bloodletting; Deferoxamine; Erythropoietin; Female; Ferritins; Hematocrit; Humans; Iron; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Transfusion Reaction | 1989 |
[Inhibition of heme biosynthesis in erythroid precursors (BFU-e) isolated from human peripheral blood: effects on globin synthesis].
Topics: Chromatography, Ion Exchange; Deferoxamine; Erythroblasts; Erythropoietin; Globins; Heme; Humans; Kinetics; Protein Biosynthesis | 1983 |
Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line; Chelating Agents; Cobalt; Deferoxamine; Endothelial Growth Factors; Erythropoietin; Gene Expression Regulation, Neoplastic; Growth Substances; Humans; Liver Neoplasms; Lymphokines; Molecular Sequence Data; Neovascularization, Pathologic; Placenta Growth Factor; Platelet-Derived Growth Factor; Pregnancy Proteins; RNA, Messenger; RNA, Small Nuclear; Transforming Growth Factor beta; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1995 |
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferoxamine; Erythrocyte Count; Erythropoietin; Female; Follow-Up Studies; Hemochromatosis; Humans; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Recombinant Proteins; Remission Induction; Transfusion Reaction; Treatment Outcome | 1994 |
Successful treatment of haemodialysis-related porphyria cutanea tarda with erythropoietin.
Topics: Deferoxamine; Erythropoietin; Female; Humans; Middle Aged; Porphyria Cutanea Tarda; Recombinant Proteins; Renal Dialysis | 1994 |
Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.
Topics: Base Sequence; Cell Hypoxia; Cell Line; Cell Nucleus; Cobalt; Deferoxamine; DNA-Binding Proteins; Erythropoietin; Gene Expression; Hepatoblastoma; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Molecular Sequence Data; Nuclear Proteins; Oligonucleotide Probes; RNA, Neoplasm; Signal Transduction; Transcription Factors; Tumor Cells, Cultured | 1993 |
Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
Topics: Aged; Aluminum; Anemia, Hypochromic; Deferoxamine; Erythropoietin; Ferritins; Hematocrit; Hemoglobins; Humans; Iron; Middle Aged; Recombinant Proteins; Renal Dialysis; Transferrin | 1993 |
Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
Topics: Aluminum; Anemia; Deferoxamine; Drug Resistance; Erythropoietin; Humans; Kidney Failure, Chronic; Middle Aged; Recombinant Proteins; Renal Dialysis | 1993 |
Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia. Implications for the mechanism of oxygen sensing.
Topics: Base Sequence; Biphenyl Compounds; Cobalt; Deferoxamine; DNA-Binding Proteins; Enhancer Elements, Genetic; Erythropoietin; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Sequence Data; Nuclear Proteins; Oligodeoxyribonucleotides; Onium Compounds; Oxygen; Transcription Factors; Tumor Cells, Cultured | 1995 |
Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarities with the regulation of erythropoietin.
Topics: Base Sequence; Cell Hypoxia; Cell Line; Cobalt; Deferoxamine; Energy Metabolism; Erythropoietin; Gene Expression Regulation; Glycolysis; HeLa Cells; Humans; Isoenzymes; Mitochondria; Molecular Sequence Data; Monosaccharide Transport Proteins; Oligonucleotide Probes; RNA, Messenger; Siderophores | 1996 |
Hypoxia signalling in the control of erythropoietin gene expression in rat hepatocytes.
Topics: Animals; Catalase; Cell Hypoxia; Cells, Cultured; Cobalt; Cycloheximide; Deferoxamine; DNA-Binding Proteins; Erythropoietin; Gene Expression Regulation; Hydrogen Peroxide; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Liver; Male; Nuclear Proteins; Oxygen; Protein Biosynthesis; Rats; Rats, Sprague-Dawley; RNA; Signal Transduction; Transcription Factors | 1996 |
The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.
Topics: Adolescent; Aged; Bone Marrow Diseases; Chromosome Aberrations; Deferoxamine; Erythropoietin; Female; Follow-Up Studies; Hematopoiesis; Hemoglobins; Hemosiderosis; Humans; Iron; Karyotyping; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Receptors, Transferrin; Transfusion Reaction; Treatment Outcome | 1996 |
Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis.
Topics: Anemia; Arthritis, Rheumatoid; Chronic Disease; Deferoxamine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Erythropoietin; Female; Ferritins; Follow-Up Studies; Humans; Infusions, Parenteral; Interleukin-6; Iron; Male; Middle Aged; Siderophores; Treatment Outcome | 1996 |
Cobalt and desferrioxamine reveal crucial members of the oxygen sensing pathway in HepG2 cells.
Topics: Cell Line; Cobalt; Cytochromes; Deferoxamine; Erythropoietin; Fluorescent Dyes; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Models, Molecular; NADPH Oxidases; Oxygen; Oxygen Consumption; Reactive Oxygen Species; Rhodamine 123; Rhodamines | 1997 |
Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species.
Topics: Cell Line; Cobalt; Deferoxamine; Erythropoietin; Humans; Hydrogen Peroxide; NADP; Reactive Oxygen Species; Signal Transduction | 1997 |
[Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
Topics: Adult; Aluminum; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 1996 |
Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
Topics: Aluminum; Deferoxamine; Drug Resistance; Erythropoietin; Female; Ferritins; Hematocrit; Humans; Iron; Male; Middle Aged; Recombinant Proteins; Renal Dialysis | 1998 |
Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity.
Topics: Animals; Antimutagenic Agents; Base Sequence; Cell Hypoxia; Chelating Agents; Cobalt; Deferoxamine; DNA; DNA-Binding Proteins; Endothelial Growth Factors; Enzyme Inhibitors; Erythropoietin; Fibroblasts; Gene Expression Regulation, Neoplastic; Hepatoblastoma; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Lymphokines; Mersalyl; Nuclear Proteins; Phosphopyruvate Hydratase; Rats; Receptor, IGF Type 1; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Effects of pro- and antioxidative compounds on renal production of erythropoietin.
Topics: Animals; Antioxidants; Chelating Agents; Deferoxamine; Erythropoietin; Free Radical Scavengers; Hydrogen Peroxide; Hypoxia; In Vitro Techniques; Kidney; Male; Oxidants; Pyrogallol; Rats; Rats, Sprague-Dawley; Reference Values; RNA, Messenger; Thiourea; Vitamin A | 1999 |
Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling.
Topics: Aryl Hydrocarbon Receptor Nuclear Translocator; Carbon Monoxide; Cell Hypoxia; Cell Line; Cobalt; Cyclic GMP; Cysteine; Deferoxamine; DNA-Binding Proteins; Erythropoietin; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Nitric Oxide; Nitroprusside; Nuclear Proteins; Oxygen; Receptors, Aryl Hydrocarbon; RNA, Messenger; Transcription Factors; Transcriptional Activation; Transfection | 1999 |
Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Colony-Forming Units Assay; Deferoxamine; Drug Synergism; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins | 1999 |
Regulation of erythropoietin gene expression depends on two different oxygen-sensing mechanisms.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Cycloheximide; Deferoxamine; Erythropoietin; Gene Expression Regulation; Humans; Oxygen; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
Erythropoietin production: evidence for multiple oxygen sensing pathways.
Topics: Chelating Agents; Cobalt; Deferoxamine; Erythropoietin; Humans; Iron Chelating Agents; Oxygen; Partial Pressure; Reactive Oxygen Species; Sulfhydryl Reagents; Tumor Cells, Cultured | 1999 |
Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and ery
Topics: Activating Transcription Factor 1; Animals; Apoptosis; Cells, Cultured; Cerebral Cortex; Chelating Agents; Cobalt; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deferoxamine; DNA-Binding Proteins; Enzyme Induction; Erythropoietin; Fetus; Fructose-Bisphosphate Aldolase; Gene Expression Regulation; Glutathione; Glycolysis; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; L-Lactate Dehydrogenase; Mimosine; Neurons; Neuroprotective Agents; Nuclear Proteins; Oxidative Stress; Rats; Rats, Sprague-Dawley; Transcription Factors | 1999 |
Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Topics: Anemia; Chelating Agents; Deferoxamine; Erythropoiesis; Erythropoietin; Female; Ferritins; Humans; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis | 1999 |
Erythropoietin induction in Hep3B cells is not affected by inhibition of heme biosynthesis.
Topics: Cell Survival; Deferoxamine; Enzyme Inhibitors; Erythropoietin; Heme; Heptanoates; Humans; Isoniazid; Protoporphyrins; Tumor Cells, Cultured | 2000 |
Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adult; Arrhythmias, Cardiac; beta-Thalassemia; Chelation Therapy; Chromosomes, Human, Pair 1; Deferoxamine; Erythropoietin; Estrogen Replacement Therapy; Female; Hemochromatosis; Hemosiderosis; Hormone Replacement Therapy; Humans; Hypogonadism; Liver Cirrhosis; Phlebotomy; Progesterone; Recombinant Proteins | 2000 |
Bone aluminum uptake in uremic rats receiving intraperitoneal iron.
Topics: Aluminum; Animals; Bone and Bones; Deferoxamine; Erythropoietin; Iron; Male; Rats; Rats, Wistar; Renal Insufficiency; Uremia | 2001 |
Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro.
Topics: Animals; Cell Survival; Cells, Cultured; Cerebral Cortex; Constriction; Cycloheximide; Deferoxamine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Embryo, Mammalian; Erythropoietin; Gene Expression; Glucose; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Ischemic Attack, Transient; Male; Middle Cerebral Artery; Neurons; Nuclear Proteins; Oxygen; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Reperfusion; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors | 2002 |
Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin.
Topics: Blood Cell Count; Bone Marrow; Child, Preschool; Deferoxamine; Disease Susceptibility; Dyskeratosis Congenita; Erythropoietin; Ferritins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Pancytopenia; Respiratory Tract Infections | 2003 |
Novel function of neuronal PAS domain protein 1 in erythropoietin expression in neuronal cells.
Topics: Animals; Animals, Newborn; Aryl Hydrocarbon Receptor Nuclear Translocator; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Brain; Cell Hypoxia; Cell Line; Chromatin; Deferoxamine; DNA-Binding Proteins; Embryo, Mammalian; Erythropoietin; Gene Expression; Gene Expression Regulation; Green Fluorescent Proteins; Helix-Loop-Helix Motifs; Humans; Immunohistochemistry; Immunoprecipitation; Iron Chelating Agents; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Nerve Tissue Proteins; Neurons; Receptors, Aryl Hydrocarbon; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Staining and Labeling; Transcription Factors; Transfection | 2005 |
Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke.
Topics: Animals; Animals, Newborn; Blotting, Western; Deferoxamine; Disease Models, Animal; Erythropoietin; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Immunohistochemistry; Infarction, Middle Cerebral Artery; Iron Chelating Agents; Phosphopyruvate Hydratase; Rats; Time Factors; Up-Regulation | 2005 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Comorbidity; Deferoxamine; Disease-Free Survival; Erythrocyte Transfusion; Erythropoietin; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hemosiderosis; Humans; Hydroxyurea; Immunosuppressive Agents; Iron Chelating Agents; Life Tables; Liver Cirrhosis; Male; Phlebotomy; Postoperative Complications; Survival Analysis; Thalassemia; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Regulation of hepcidin in HepG2 and RINm5F cells.
Topics: Animals; Antimicrobial Cationic Peptides; Cell Line; Cell Line, Tumor; Cell Survival; Deferoxamine; Dose-Response Relationship, Drug; Erythropoietin; Gene Expression Regulation; Hepcidins; Humans; Immunoblotting; Interleukin-6; Iron; Lipopolysaccharides; Microscopy, Fluorescence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin.
Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Deferoxamine; Disease Models, Animal; Erythropoietin; Fluorescent Antibody Technique; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Ischemia, Brain; Infarction, Middle Cerebral Artery; Iron; Ischemic Preconditioning; Nerve Degeneration; Neurons; Rats; Rats, Sprague-Dawley; Siderophores; Time Factors; Treatment Outcome; Up-Regulation | 2008 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Combination of deferoxamine and erythropoietin: therapy for hypoxia-ischemia-induced brain injury in the neonatal rat?
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Antioxidants; Brain Infarction; Caspase 3; Cerebral Cortex; Cytoprotection; Deferoxamine; Disease Models, Animal; Drug Combinations; Drug Synergism; Erythropoietin; Hypoxia-Ischemia, Brain; Microtubule-Associated Proteins; Myelin Basic Protein; Nerve Degeneration; Nerve Fibers, Myelinated; Neurons; Rats; Rats, Wistar | 2009 |
The extract of Rhodiolae Crenulatae Radix et Rhizoma induces the accumulation of HIF-1α via blocking the degradation pathway in cultured kidney fibroblasts.
Topics: Cells, Cultured; Deferoxamine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Erythropoietin; Fibroblasts; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney; Mixed Function Oxygenases; Plant Roots; Recombinant Fusion Proteins; Response Elements; Rhizome; Rhodiola; RNA, Messenger; Siderophores; Transcriptional Activation | 2011 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles | 2011 |
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Deferoxamine; Erythropoietin; Health Status Indicators; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Siderophores; Thalidomide | 2012 |
Cross-talk between microRNAs, nuclear factor E2-related factor 2, and heme oxygenase-1 in ochratoxin A-induced toxic effects in renal proximal tubular epithelial cells.
Topics: Acetylcysteine; Animals; Antioxidants; Cells, Cultured; Deferoxamine; Epithelial Cells; Erythropoietin; Gene Expression Regulation; Heme Oxygenase-1; Kidney Tubules, Proximal; MicroRNAs; NF-E2-Related Factor 2; Ochratoxins; Reactive Oxygen Species; Signal Transduction; Swine; Transforming Growth Factor beta | 2013 |
A functional role of the cyclin-dependent kinase inhibitor 1 (p21(WAF1/CIP1)) for neuronal preconditioning.
Topics: Animals; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; Deferoxamine; Erythropoietin; Gene Expression Regulation; Hypoxia-Inducible Factor 1; Hypoxia, Brain; Ischemic Preconditioning; Mice; Mice, Knockout; Mutation; Nerve Tissue Proteins; Siderophores | 2013 |
The role of HIF in cobalt-induced ischemic tolerance.
Topics: Amino Acids, Dicarboxylic; Animals; Astrocytes; Brain Ischemia; Cell Survival; Cells, Cultured; Cobalt; Deferoxamine; Erythropoietin; Hippocampus; Hypoxia-Inducible Factor 1; Immunohistochemistry; Ischemic Preconditioning; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Polymerase Chain Reaction; Prolyl-Hydroxylase Inhibitors | 2013 |
Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells.
Topics: Amino Acids, Dicarboxylic; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cobalt; Deferoxamine; Erythropoietin; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Phosphoglycerate Kinase; Promoter Regions, Genetic; Propanolamines; Protein Binding; Pyrrolidines; RNA, Messenger; Superoxide Dismutase; Transcription, Genetic; Upstream Stimulatory Factors | 2013 |
Aluminum overload in the reverse osmosis dialysis era: does it exist?
Topics: Alkaline Phosphatase; Aluminum; Aluminum Compounds; Anemia; Calcium; Deferoxamine; Erythropoietin; Humans; Osmosis; Phosphates; Renal Dialysis | 2022 |